Lenalidomide is active for extramedullary disease in refractory multiple myeloma

被引：0
作者：
Tomonori Nakazato
Ai Mihara
Chisako Ito
Yukinari Sanada
Yoshinobu Aisa
机构：
[1] Yokohama Municipal Citizen’s Hospital,Department of Hematology
来源：
Annals of Hematology | 2012年 / 91卷
关键词：
Multiple Myeloma; Thalidomide; Bortezomib; Lenalidomide; Bacterial Pneumonia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：473 / 474
页数：1
相关论文
共 50 条
  • [21] Extramedullary Disease in Multiple Myeloma
    Megan H. Jagosky
    Saad Z. Usmani
    Current Hematologic Malignancy Reports, 2020, 15 : 62 - 71
  • [22] Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients
    Stork, M.
    Sevcikova, S.
    Adam, Z.
    Krejci, M.
    Sandecka, V
    Kral, Z.
    Brozova, L.
    Velichova, R.
    Pour, L.
    NEOPLASMA, 2018, 65 (04) : 585 - 591
  • [23] Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
    Chen, Christine
    Reece, Donna E.
    Siegel, David
    Niesvizky, Ruben
    Boccia, Ralph V.
    Stadtmauer, Edward A.
    Abonour, Rafat
    Richardson, Paul
    Matous, Jeffrey
    Kumar, Shaji
    Bahlis, Nizar J.
    Alsina, Melissa
    Vescio, Robert
    Coutre, Steven E.
    Pietronigro, Dennis
    Knight, Robert D.
    Zeldis, Jerome B.
    Rajkumar, Vincent
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (02) : 164 - 170
  • [24] Spotlight on Lenalidomide in Relapsed or Refractory Multiple Myeloma
    Scott, Lesley J.
    Lyseng-Williamson, Katherine A.
    BIODRUGS, 2011, 25 (05) : 333 - 337
  • [25] An update on the use of lenalidomide for the treatment of multiple myeloma
    Zagouri, Flora
    Terpos, Evangelos
    Kastritis, Efstathios
    Dimopoulos, Meletios-Athanasios
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (12) : 1865 - 1877
  • [26] Thalidomide and lenalidomide in multiple myeloma
    Mazumder, Amitabha
    Jagannath, Sundar
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 769 - 780
  • [27] Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
    Abdallah, Al-Ola
    Mohyuddin, Ghulam Rehman
    Ahmed, Nausheen
    Mohan, Meera
    Cui, Wei
    Shune, Leyla
    Mahmoudjafari, Zahra
    McGuirk, Joseph
    Ganguly, Siddhartha
    Atrash, Shebli
    EJHAEM, 2021, 2 (04): : 757 - 764
  • [28] Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment
    Manola Zago
    Katharina Oehrlein
    Corinna Rendl
    Corinna Hahn-Ast
    Lothar Kanz
    Katja Weisel
    Annals of Hematology, 2014, 93 : 1993 - 1999
  • [29] Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma
    Bilotti, Elizabeth
    Vesole, David H.
    McBride, Laura
    Schmidt, Linda
    Gao, Zhijie
    Gilani, Madiha
    McNeill, Ann
    Bednarz, Urszula
    Richter, Joshua
    Mato, Anthony
    Graef, Thorsten
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (10) : 558 - 562
  • [30] Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment
    Zago, Manola
    Oehrlein, Katharina
    Rendl, Corinna
    Hahn-Ast, Corinna
    Kanz, Lothar
    Weisel, Katja
    ANNALS OF HEMATOLOGY, 2014, 93 (12) : 1993 - 1999
12345